ClinicalTrials.gg
SuspendedNCT06840574Updated Feb 23, 2026

The Effect of Nutritional Supplementation on Actinic Purpura: A Pilot Study

An interventional study of Cyruta Plus: A Whole-Food Based Vitamin C supplement containing organic buckwheat (aerial parts) juice powder, organic buckwheat flour, bovine adrenal Cytosol™ extract, oat flour, honey, ascorbic acid and Low Dose Vitamin C in Skin Health, Skin Aging of Face and Hands and Healthy, sponsored by Standard Process Inc.. Suspended at 1 site in United States. Open to participants aged 55 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-23.

Sponsored by Standard Process Inc. · Not applicable, Interventional, and Other

Why this study was suspended
Change in sponsor priority.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Study summary

Purpura is a macule or papule of blood in the skin. It is mostly seen in mature skin that is often prone to significant bruising. Small lesions of less than 5 mm are called petechiae and larger ones, found mostly in subcutaneous tissue, are called ecchymosis. Actinic purpura occurs almost exclusively in elderly populations. This single-blind randomized clinical trial evaluates the effect of an 8-week nutritional supplement intervention in comparison with isolated vitamin C supplements on actinic purpura in older adults. We will enroll thirty (30) otherwise healthy participants, both male and female, aged 55 years and older. Changes in participants' skin condition will be assessed at visit 1 (baseline), visit 2 (4-week), and visit 3 (8-week) using questionnaires, standard digital photography, and clinical grading of the skin lesions.

02

Conditions studied

  • Skin Health
  • Skin Aging of Face and Hands
  • Healthy
  • Ecchymosis

Browse trials for

03

In context

Ecchymosis

38 studies on the registry are indexed under Ecchymosis; 6 are open to participants now.

This study's planned enrollment of 30 is below the median of 66 across 34 interventional studies indexed under Ecchymosis.

Browse Ecchymosis studies →

Lead sponsor

Standard Process Inc. is the lead sponsor of 11 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female individuals aged ≥ 55 years old.
  • Self-reported having actinic purpura lesions at the time of enrollment or a history of actinic purpura lesions.
  • Self-reported not using prescription or over-the-counter products that contain aluminum, iron, proton pump inhibitors (PPIs), and/or topical retinol (used locally in areas of bruising).
  • If on a chronic medication that does not result in exclusion, participant must self-report being on a stable dose for the last 3 months prior to the start of the trial.
  • Able and willing to read and voluntarily sign the study Form (ICF).
  • Able and willing to comply with study protocol and all study-related guidelines.
  • Not concomitantly participating in a study involving nutritional products.

Exclusion criteria

Exclusion Criteria:

  • Not complying with the study protocol.
  • Having a known allergy or intolerance to nuts, seeds, fruits, vegetables, oils, and fish.
  • Having a known allergy, intolerance, or dietary restriction to any of the study ingredients (Vitamin C, organic buckwheat (aerial parts) juice powder, organic buckwheat flour, bovine adrenal Cytosol™ extract, oat flour, honey, ascorbic acid, and calcium stearate).
  • Having a condition that is severe, progressive, or uncontrolled and would compromise the study or their well-being or would prevent the participant from meeting or performing study requirements. This includes but is not limited to dysphagia (or difficulty swallowing), liver or kidney disease, bone marrow problems, Ehlers-Danlos syndrome, lupus, alcohol misuse, cancer, or and other infections.
  • Having active dermatological conditions. Patients with active, severe skin conditions that might interfere with the study's conduct or outcomes including widespread psoriasis, untreated chronic skin ulcers, or other severe dermatological disorders.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Cyruta Plus

    Total of 27 mg daily

    Dietary Supplement: Cyruta Plus: A Whole-Food Based Vitamin C supplement containing organic buckwheat (aerial parts) juice powder, organic buckwheat flour, bovine adrenal Cytosol™ extract, oat flour, honey, ascorbic acid

  • Active comparator
    Low-dose Vitamin C

    Total of 27 mg daily

    Dietary Supplement: Low Dose Vitamin C

  • Active comparator
    High-dose Vitamin C

    Total of 500 mg daily

    Dietary Supplement: High Dose Vitamin C

Interventions

  • Dietary supplementCyruta Plus: A Whole-Food Based Vitamin C supplement containing organic buckwheat (aerial parts) juice powder, organic buckwheat flour, bovine adrenal Cytosol™ extract, oat flour, honey, ascorbic acid

    27 mg vitamin C, organic buckwheat (aerial parts) juice powder, organic buckwheat flour, bovine adrenal Cytosol™ extract, oat flour, honey, ascorbic acid, and calcium stearate

  • Dietary supplementLow Dose Vitamin C

    27 mg ascorbic acid

  • Dietary supplementHigh Dose Vitamin C

    500 mg ascorbic acid

06

What researchers measure

Primary outcomes

  1. Primary Endpoint

    The number of participants who report a reduction in the number of purpura lesions as evaluated through dermatological examination before and after supplementation.

    Time frame: 8 weeks

Secondary outcomes

  1. Secondary Endpoint

    Average decrease in actinic purpura lesion measurements in millimeters across participants.

    Time frame: 8 weeks

07

Study locations

1 site
  • Standard Process - Nutrition Innovation Center
    Kannapolis, North Carolina 28081, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Apr 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2025
First posted
Feb 21, 2025
StartActual
Apr 1, 2025
Primary completionEst.
Apr 30, 2026
CompletionEst.
Apr 30, 2027
Last update
Feb 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06840574
Lead sponsor
Standard Process Inc.
Responsible party
Sponsor
First posted
Feb 21, 2025
Start date
Apr 1, 2025
Primary completion
Apr 30, 2026 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Feb 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ascorbic Acid

Start the discussion